Metabolomic profiling of end-stage heart failure secondary to chronic chagas cardiomyopathy

Martha Lucía Díaz, Karl Burgess, Richard Burchmore, María Adelaida Gómez, Sergio Alejandro Gómez-Ochoa, Luis Eduardo Echeverría, Carlos Morillo, Clara Isabel González*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Chronic Chagas cardiomyopathy (CCC) is the most frequent and severe clinical form of chronic Chagas disease, representing one of the leading causes of morbidity and mortality in Latin America, and a growing global public health problem. There is currently no approved treatment for CCC; however, omics technologies have enabled significant progress to be made in the search for new therapeutic targets. The metabolic alterations associated with pathogenic mechanisms of CCC and their relationship to cellular and immunopathogenic processes in cardiac tissue remain largely unknown. This exploratory study aimed to evaluate the potential underlying pathogenic mechanisms in the failing myocardium of patients with end-stage heart failure (ESHF) secondary to CCC by applying an untargeted metabolomic profiling approach. Cardiac tissue samples from the left ventricle of patients with ESHF of CCC etiology (n = 7) and healthy donors (n = 7) were analyzed using liquid chromatography-mass spectrometry. Metabolite profiles showed altered branched-chain amino acid and acylcarnitine levels, decreased fatty acid uptake and oxidation, increased activity of the pentose phosphate pathway, dysregulation of the TCA cycle, and alterations in critical cellular antioxidant systems. These findings suggest processes of energy deficit, alterations in substrate availability, and enhanced production of reactive oxygen species in the affected myocardium. This profile potentially contributes to the development and maintenance of a chronic inflammatory state that leads to progression and severity of CCC. Further studies involving larger sample sizes and comparisons with heart failure patients without CCC are needed to validate these results, opening an avenue to investigate new therapeutic approaches for the treatment and prevention of progression of this unique and severe cardiomyopathy.

Original languageEnglish
Article number10456
Number of pages18
JournalInternational Journal of Molecular Sciences
Issue number18
Publication statusPublished - 9 Sept 2022

Keywords / Materials (for Non-textual outputs)

  • chronic chagas cardiomyopathy
  • heart failure
  • metabolites
  • metabolomics


Dive into the research topics of 'Metabolomic profiling of end-stage heart failure secondary to chronic chagas cardiomyopathy'. Together they form a unique fingerprint.

Cite this